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ABSTRACT
To identify novel antimalarials from unexplored areas of chemical space, we have utilized two
approaches: (a) using Torrey Pines Institute for Molecular Studies (TPIMS) proprietary highdensity combinatorial libraries containing a large number of small molecule compounds residing
largely in the underexplored areas of chemical space; and, (b) using novel, complexity-todiversity/ring distortion of available natural products. The first approach involved the screening of
more than 30 million compounds derived from 81 small molecule libraries, built on 81 distinct
scaffolds. From this, we identified the pyrrolidine bis-cyclic guanidine library (TPI-1955) to be
one of the most active and selective for antiplasmodial activity. In parallel, the synthesis of
individual compounds derived from the deconvolution of the positional scanning library led to the
identification of active selective antiplasmodial pyrrolidine bis cyclic guanidines.

In the

complexity to diversity/ring distortion approach, the indole alkaloid, yohimbine, has been reengineered to alter the it’s biological activity through a ring rearrangement synthesis pathway to
develop a new series of antiplasmodial agents. One such antiplasmodial agent, Y7j, demonstrated
good potency against the chloroquine-resistant Dd2 strain of parasites without eliciting
cytotoxicity against human HepG2 cells. Y7j demonstrated stage specific action against
plasmodium parasites in the late ring/trophozoite stage, and demonstrates the potential for ring
distortion to drive new discoveries and change existing paradigms in both chemical biology and
drug discovery.
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CHAPTER 1: INTRODUCTION
1.1.Malaria: A Global Scourge
Malaria is an infection caused by parasites of the Plasmodium species, single-celled parasites
spread by the female Anopheles mosquito. Once the Plasmodium parasite reaches the bloodstream,
it begins to infect and destroy liver and red blood cells (RBCs), causing a variety of symptoms and
sometimes death [1,2,3]. Despite efforts to eradicate the disease, the latest World Malaria Report
indicated there were 216 million reported cases of malaria in 2016, with nearly half a million
fatalities [1,2,3]. Malaria therefore is a serious global health problem affecting millions of people;
in particular, young children under the age of 5, pregnant women, patients with other health
conditions such as HIV and AIDs, and travelers who have had no prior exposure [1,2,3]. In total,
more than 2 billion people are at risk of malaria [1,2,3]. Tropical and subtropical regions including
South America, sub-Saharan Africa, South Asia and Southeast Asia are the most affected [1,2,3].
Malaria was once prevalent in temperate areas such as United States; but was later eliminated
through widespread spraying of the insecticide dichlorophenyl-trichloroethane (DDT) throughout
the southern US during the late 1940’s and early 1950’s [4].
There are hundreds Plasmodium species, but only 5 cause malarial disease in humans;
Plasmodium falciparum (P. falciparium), Plasmodium vivax, Plasmodium malariae, Plasmodium
ovale, and Plasmodium knowlesi [1,2,3,4]. Plasmodium falciparum is responsible for the most
human deaths annually; while the more frequent is Plasmodium vivax which uses a specific
erythrocyte surface receptor called the Duffy antigen [1, 2, 3, 4, 5]. Some individuals, particularly
those with sickle-cell anemia, lack the Duffy antigen. As a result, Plasmodium vivax cannot get
enter their cells [6]. Therefore, having sickle cell anemia results in relative protection from
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Plasmodium vivax. Other diseases, like thalassemia and G6PD deficiency, make the parasiteinfected erythrocyte more susceptible to dying from oxidative stress [6]. Despite the obvious
disadvantages to having these diseases, they do offer an advantage in regards to warding off a
malaria infection [6]. In fact, because malaria has historically circulated in Africa, the genes
underlying these diseases are thought to have conferred a natural selection advantage, and have
become more common in the genetic pool for endemic areas [6].
1.2. Complex Life Cycle of the Malaria Parasite
Malaria begins when a plasmodium-infected female Anopheles mosquito hunts for a blood
meal in the evening and throughout the night [1,2,3,6]. This mosquito is attracted to carbon
dioxide, as well as other bodily olfactory secretions released by humans. At this point, the
Plasmodium parasite is located in the mosquito’s salivary gland in a stage of development called
sporozoite [1,2,3,6].
The mosquito uses a needle-like structure, called a proboscis, to pierce a human’s skin in
order to take a blood meal (Figure 1). While the mosquito takes a blood meal from a human,
sporozoites spill into the individuals blood stream [1,2]. Within minutes, the sporozoites reach the
liver and invade hepatocytes, where they begin asexual reproduction through a process known as
schizogony [2].Over the next 1-2 weeks, Plasmodium falciparum, Plasmodium malariae, and
Plasmodium knowlesi sporozoites will multiply asexually and mature into thousands of daughter
merozoites, leading to host hepatocyte death [1,2,3,4,6]. In contrast, Plasmodium vivax and
Plasmodium ovale sporozoites can enter into a dormant hepatic phase, known as the hypnozoite
phase [1,2,3]. Hypnozoites do not divide, instead, they lay dormant for an indefinite period of time
prior to entering the process of schizogony, possibly leading to a long delay between the initial
infection and disease symptoms[1,2,3].
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Figure 1. Plasmodial Life Cycle. Source: https://www.cdc.gov/malaria/about/biology/
index.html

Once the merozoites are released into the blood, each one may bind to a surface receptor
and invades a red blood cell (RBC) [1,2,3]. This is called the exoerythrocytic phase because
parasite reproduction occurs outside of the erythrocyte. The exoerythrocytic phase is generally
asymptomatic [2,4,6]. Once inside the RBC, the merozoite undergoes asexual reproduction and
a series of transformational changes. This phase is known as the intraerythrocytic stage of malaria,
because it happens inside of the red blood cell, and generally lasts around 2 days [1,2,4,6]. It is
during the intraerythrocytic asexual growth cycle when clinical symptoms begin to manifest
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[1,2,4,6]. Over the course of 48 hours, the parasite will progress through four distinct stages
[1,2,3,4,6]. For the first 16 hours post invasion (HPI), during what is titled the ring stage, the
parasite grow within the blood cell as a small ring shape [1,2,3,4,6]. Following the ring stage, at
roughly 16 HPI, the parasite begins the trophozoite stage [1,2,3,4,6]. During the trophozoite stage,
the parasite grows by digesting host cell hemoglobin and expands further into the host cell’s
environment. Towards the end of the trophozoite stage, the parasite enters into S phase and begins
to rapidly reproduce its nucleic acid content [1]. At roughly 30 HPI, in a process known as
schizogony, the parasite begins to undergo multiple rounds of asynchronous nuclear division
without cytokinesis to produce approximately 8 to 20 new daughter merozoites [1]. This process
continues until segmentation, when daughter cells undergo a single round of synchronous division
followed by cytokinesis. Shortly after segmentation, the parasites egress from the host erythrocyte
and invade other erythrocytes, perpetuating the cycle of asexual production.
Alternatively, rather than committing to the erythrocytic phase, a small number of
merozoites undergo sexual differentiation through the processes of gametogony where they divide
and give rise to gametocytes which can be either male or female [1]. Gametocytes remain inside
of the red blood cell and may be ingested by another Anopheles mosquito that takes a blood meal
from an infected individual [1]. The gametocytes then travel to the mosquito’s midgut where they
mature once more before the male and female fuse to form a zygote [1]. This phase of the
plasmodium life cycle is called sporogony, a form of sexual reproduction; as opposed to
schizogony or asexual reproduction that occurs in the liver and red blood cells [1]. The zygote
further develops into an ookinete before becoming an oocyst that ruptures in the mosquito’s gut,
releasing thousands of sporozoites. These navigate their way into the mosquito’s salivary gland in
order to repeat the cycle of infection once again[1].
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The incubation time, or the period of time between infection and symptom onset, varies
depending on the Plasmodium species [1]. Plasmodium falciparum incubates for only a few days,
whereas Plasmodium malariae incubates for a few weeks [1]. The release of tumor necrosis factor
alpha and other inflammatory cytokines causes fevers that typically occur in paroxysms, or short
bursts, and corresponds to the rupture of the infected red blood cells which happens in waves of
reproductive cycles unique to each Plasmodium species [1]. For Plasmodium malariae, fevers
happen every 72 hours, and are called quartan fevers. For Plasmodium vivax and Plasmodium
ovale, fevers happen every 48 hours, and these are called tertian fevers; meaning that the fever
occurs every second day of parasite infection. For Plasmodium knowlesi, a tertian fever happens
every 24 hours. For Plasmodium falciparum, the fever occurs at 24 and 48 hours, and is called a
malignant tertian fever because the length of the fever is more intense than other fevers caused by
Plasmodium. In addition to fevers, the hemolytic anemia, which is the destruction of red blood
cells, also causes symptoms like extreme fatigue, headaches, jaundice, and splenomegaly. Most
plasmodium infections have a mild course of symptoms and are regarded as uncomplicated
malarial infections.
Out of all of the Plasmodium species, Plasmodium falciparum is known for causing the
greatest number of fatal infections. Most plasmodium-infected red blood cells get screened and
destroyed by the spleen. Plasmodium falciparum however, generates a sticky protein that coats the
surface of infected red blood cells, forming “knobs” to avoid destruction by the spleen. This protein
promotes cytoadherence which causes red blood cells to clump together, resulting in clots in small
blood vessels and blocking the flow of blood such that infected cells are unable to flow into the
spleen. Additionally, these clumps can block blood flow from reaching other vital organs.
Between hemolytic anemia and ischemic damage from blocked blood flow, organ-failure can set
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in relatively quickly. If the brain is affected, its termed cerebral malaria. Cerebral malaria results
in altered mental status, seizures, and coma. If the liver is affected, its termed bilious malaria, and
can results in diarrhea, vomiting, jaundice, and liver failure [1,4,6]. Other commonly affected
organs include the lungs, the kidneys, and the spleen, which taken together create a sepsis-like
clinical picture called complicated malaria that can eventually lead to death.
Malaria is usually diagnosed with a thick blood smear to locate parasites within red blood
cells; and a thin blood smear, which is used to identify the Plasmodium species. One key to
diagnosis and treatment is to ascertain the percentage of red blood cells infected by parasites, or
the parasitemia. High parasitemia, beyond 5% infected red blood cells, is indicative of poor
projected outcomes. Additionally, a high plasmodial infection can cause thrombocytopenia,
elevated lactate dehydrogenase resulting from hemolysis, and a normochromic and normocytic
anemia [1,4,6]. In addition, blood smears may be used to identify the stage of infection. This is
important as treatment for malaria is generally divided into the different stages of infection.
Suppressive treatment, or chemoprophylaxis, is aimed at killing sporozoites before they
infect hepatocytes. This type of preventative treatment is usually given to individuals traveling to
malaria endemic regions [1,2,3,4,6].Therapeutic treatment meanwhile, is aimed at eliminating
merozoites during the erythrocytic phase, and is given during an active infection. The exact
medication, or group of medications, that are used to treat an active infection depends largely on
the severity of the infection, the age and pregnancy status of the patient, the local malarial
resistance pattern (which depends on the geography), and the Plasmodium species causing the
infection [1]. It is also important to avoid taking the same medication to treat an active infection
that was previously used as chemoprophylaxis [1]. Gametocidal treatment is aimed at killing
gametocytes, which prevents spread of the disease, and thus, the creation of future resistant forms
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of the parasites [1]. Lastly, radical treatments may be needed to target and kill hypnozoites in the
liver in the case of a Plasmodium vivax or Plasmodium ovale infection [1].
Most cases of uncomplicated malaria resolve with treatment; however, some individuals
can still get symptoms after a period of time following recovery. This is called recurrent malaria,
and it’s broadly divided into three underlying causes: recrudescence, relapse, and reinfection [1].
Recrudescence often occurs when a treatment was ineffective at completely clearing the infection.
Given that parasites exhibiting increased fitness in the presence of a treatment can survive
following recrudesce, ineffective treatments may lead to emergence of drug resistant plasmodium
parasites. Relapse can occur when the blood was cleared of merozoites, but hypnozoites persist in
the liver and later emerge to start a new infection cycle. Reinfection occurs when an individual
was effectively treated but later becomes infected again, and is a common problem in malaria
endemic areas. While a initial infection does not make an individual immune to malaria, there is
an acquired ability to tolerate malarial infections, which relates to the degree of exposure of a
variety of different strains [1].
As malaria is spread by mosquitos, anything that prevents mosquito bites may help to
reduce the overall infection rates. Examples of insect avoidance strategies include: full body
clothing, sleeping in insecticide treated mosquito nets, and using indoor insecticide sprays.
Additionally, its known that Anopheles mosquitos lay their eggs in small, shallow collections of
freshwater. As such, it is important to empty stagnant collections of water in order to suppress
growth of the Anopheles population.
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1.3 Malaria Control Measures
1.3.1.Insecticide Treated Bed-Nets
Distribution of insecticide-treated bed-nets (ITNs), has proven to be a successful preventative
measure for decreasing the prevalence of parasite infections in malaria endemic regions [7, 8,
9,10]. Despite this, there are growing concerns that without the issuance of new ITNs, there may
be a reversal of this success. This fear is rooted in the fact that ITNs were only manufactured to
be protective for up to 3 years, and many of the existing ITNs are surpassing their shelf-life.
Additionally, there is a growing resistance to pyrethroids, the chemical class of compounds used
to treat the bed nets [11].
1.3.2. Indoor Residual Spraying
Indoor residual spraying (IRS) has historically been critical to malaria eradication
programs. However, mutations in the Anopheles’ pyrethroid knockdown resistance gene ( kdr),
has led to widespread mosquito resistance to pyrethroids, as mentioned before. This then reduces
the efficacy of ITNs and IRS and, as a result, IRS use is expected to decline [11].
1.3.3. Vaccines
An ideal means of eradicating malaria would be through the development and use of a
vaccine; and over the past two decades, large strides towards a malaria vaccine have occurred.
Recently, the RTS.S vaccine, marketed by GSK under the trade name Mosquirix, was the first
malaria vaccine to be approved by the European Medicines Agency [12,13]. The vaccine is
composed of the repeat region of the circumsporoozooite protein (CSP), combined with the
hepatitis B virus surface antigen (HBsAg), and the AS01 adjuvant [12,13]. Together, the RTS.S
vaccine prevents Plasmodium from establishing an infection [12,13,14]. While the vaccine is
generally well tolerated, the RTS vaccine offers only a moderate level of protection and is limited
by the requirements of a high number of doses to maintain efficacy, an inability to efficiently
8

deliver the vaccine across African countries, high cost, and the probable interference with maternal
antibodies against Plasmodium [15].
1.3.4. Antimalarials
Quinolines
One of the earliest treatments for Malaria was the drug quinine. Quinine is a natural
product derived from the bark of the Cinchona trees in the Andes mountains [16]. Despite its initial
effectiveness, production of Quinine was limited given the difficulty of cultivating the Cinchona
tree outside of its native habitat. This stressed the need for a synthetic route to its production.
An early quinine analog to be produced via a synthetic route was the drug chloroquine.
Unfortunately, due to inaccurate toxicity measurements, the compound was passed over and
wouldn’t be reevaluated until the mid 1940s when the US Army re-examined it [17,18]. For the
second half of the 20th century, chloroquine was the gold standard for malaria treatment. However,
the widespread use of a single drug to treat malarial infection inevitably led to the emergence of
chloroquine resistant strains [19]. The first reports of chloroquine resistance emerged from the
Mekong sub region of Cambodia, and this resistance spread into Thailand by the turn of the
following decade, eventually becoming widescale.
To better understand how resistance to a drug emerged, it is important to identify the drugs
molecular target, or mechanism of action. In the case of choloquine, the mechanism is thought to
revolve around heme digestion. As the Plasmodium parasite degrades host cell hemoglobin, free
heme (which is toxic to the parasite) begins to accumulate. In response to heme release, the parasite
sequesters the heme into hemozoin, a non-toxic pigment. Treatment with chloroquine however,
blocks this process, preventing the detoxification of heme, and ultimately killing the parasite [20,
21,22].
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A drug’s mechanism of action, should not be confused with how the parasite gains
resistance, herein referred to as its mechanism of resistance. In the case of chloroquine, resistance
developed not through mutations in the drug’s molecular target, but through mutations in reaching
the drug target. When examining parasites resistant to choloroquine, the mutatons that conferred
resistance to chloroquine were identified to be in the enhancement of transport protein known as
chloroquine resistant transporter (PfCRT). This allowed the parasite to pump chloroquine out of
the digestive vacuole, thus increasing its effective concentration [20].
Antifolates
Antifolates area class of drugs that function by blocking the production of tetrahydrofolate,
a key step in the production of both nucleic acids and amino acids. Blocking folate production
leads to the inhibition of parasite DNA synthesis, slowly preventing the parasite from progressing
through its cell cycle, and ultimately killing it. Dihydropteroate synthase (DHPS) and
dihydrofolate reductase (DHFR) are the two of the key enzymes targeted in the folate pathway
[23,24,25]. DHPS inhibition by the competitive inhibitor sulfadoxine prevents the production of
7,8 dihydropteroate and p-Aminobenzoic acid (pABA) [23,24]. DHFR inhibition by antifolates,
such as the competitive inhibitors pyrimethamine and cycloguanil, blocks the parasites ability to
convert dihydrofolate to tetrahydrofolate [25]. Despite the novelty of their target, antifolate drug
resistant Plasmodium emerged rapidly after widespread antifolate chemotherapeutic use. Genomic
sequencing revealed that the majority of antifolate drug resistant parasites had developed
mutations in DHFR and DHPS, which conferred a reduced binding affinity for these inhibitors
[25].
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Artemisinins
Artemisinin is a natural product derived from the plant Artemesia annua that has long been
used in traditional Chinese medicine [26]. While the mechanism of action is still to be determined,
resistance studies have identified a mutation in the Kelch13 propeller protein to be responsible for
its resistance [27, 28]. To date, artemisinin is the most rapid acting drug used to fight malarial
infection, with complete elimination of the parasite within 48 hours. Resistance to the artemisinin
treatment leads to a delayed parasite clearance. Interestingly, the emergence of artemisinin
resistant parasites has followed the same path as chloroquine, emerging out of the Mekong
subregion and spreading across the Asian content. To prevent an epidemic of artemisinin
resistance, the WHO suggests that artemisinin be taken in combination therapies, known as
artemisinin combination therapies (ACTs), with other inhibitors.
1.3.5. Emergence of Drug Resistance
Despite attempts at the prevention and eradication of malaria through the spread of
chemical sprays like DDT, the use of bed nets, and the application of potent drugs, malaria persists.
Widespread observations of drug resistant Plasmodium falciparum have been reported with
increasing frequency [1,2]. Many of the available drugs, the majority of which were developed
over 30 years ago, are quickly losing efficacy and new treatment methods are needed.
1.3.6. New Drugs against Malaria
To combat the rise of drug resistant Plasmodium, there is an urgent need for new
antimalarials with unique mechanisms of action. While the target based screening of inhibitors
allows for rapid target identification, it cannot screen for a multitude of antiparasitic mechanisms
within a physiologically relevant environment. Phenotypic, whole cell screening, however, may
permit the screening of inhibitor libraries in an environment that more closely mimics a real
11

infection. After, the elucidation of novel targets discovered from a phenotypic screening can aid
in the fight against drug resistant malaria through the production of first-in-class antimalarials with
no preexisting clinical tolerance [29]. Phenotypic screening also offers an unbiased approach to
identifying new malarial drug targets. Using this approach, phenotypic changes in cells may be
monitored to identify new bioactive compounds. The molecular diversity of screening libraries are
key drivers in the discovery of novel antimalarials utilizing a phenotypic screening approach [32].
New and unique chemical matter must first be developed, with the hypothesis that structurally
unique drugs are more likely to have unique biological targets [30].
Novel compounds may be designed by utilizing chemical biology. One objective of
chemical biology, is to identify small molecules as useful research tools for probing biological
systems through phenotypic changes [31]. Small molecules may offer a high degree of rapid, yet
often reversible control over a biological system, in addition to the perturbation of the function of
a protein of interest [31]. By identifying an inhibitor’s mechanism of action at the molecular level,
first-in-class drugs can be then be rationally developed for chemotherapeutic use and screened in
target based assays to optimize an inhibitor for an otherwise previously unknown or “undruggable”
target [30].
Historically, natural products (NPs) have been at the center of drug design. Natural
products possess unique structural elements that have been pre-validated by nature over the period
of millions of years to interact with biological macromolecules [33]. The complexity of natural
products, or natural product-based pharmacophores, has presented major synthetic and medicinal
chemistry challenges. The challenges associated with developing natural products and natural
product-based compounds has led to a bias in the choice of libraries for screening [31]. As a result,
many large-scale screening programs have directed their attention towards large synthetic libraries.
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Despite the scale of their screening, these large synthetic libraries lack structural diversity, and
have failed to produce viable antimalarials [34].
1.3.7. Contemporary Large-Scale Screening: GSK and St. Jude Screening Libraries
Modern screening campaigns utilizing small synthetic inhibitors have been largely
unsuccessful in identifying novel antimalarials. Contemporary large scale screening libraries, such
as the GSK and St. Jude libraries, have been designed with a focus on druglike pharmacokinetic
properties such as predicted absorption, distribution, metabolism. The St. Jude Children’s Hospital
group has screened 300,000 compounds against intraerythrocytic P. falciparum (3D7 strain) at a
concentration of 7 µM [35]. The most efficacious 1,300 of these compounds were subjected to
dose response experiments against multiple strains of P. falciparum, as well as counter-screening
against multiple mammalian cell lines. This lead to 560 validated hits demonstrating a potency at
concentrations less than 2 µM against all strains of Plasmodium tested, and at least a 10-fold
selectivity for parasites against mammalian cells. The structurally diverse set of 170 compounds
was selected from these hits, and subjected to extensive profiling designed to illuminate the
mechanisms of action.
Of the validated hits that were fully profiled, 80% appeared to have novel mechanisms of
action, and showed no cross-resistance to existing drugs. The GSK library consists of roughly
2,000,000 compounds which have been screened against intraerythrocytic P. falciparum [36]. In
those screens, more than 19,000 primary hits inhibited plasmodial growth by more than 80% at 2
µM. When tested at 10 µM, only 1,982 compounds blocked HepG2 growth by more than 50%,
leaving roughly 11,500 validated scaffolds. The St. Jude’s library shared a 63% similarity to the
GSK screening library. However, while there is a high degree of similarity at the scaffold level
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between the St. Jude and GSK screening libraries, the two libraries share a low level of similarity
to pre-existing drugs (roughly 25%) [35,36].
1.3.8. Novel Approaches for Screening Compounds: Positional Scanning Synthetic
Combinatorial Libraries
Positional screening libraries possess a mixture of peptides, and/or amino acids, having
one or more fixed positions at a discrete amino acid, while allowing the remaining positions to be
comprised of a mixture [42]. These libraries are arranged such that each sample contains close
structural analogues based on a common core scaffold [42]. Using combinatorial chemistry,
positional scanning combinatorial libraries can be rapidly synthesized and analyzed. This approach
provides the ability to determine the effect of the fixed amino acids, independent of the residues
in the remaining positions [42]. This approach offers an advantage over traditional screening,
which requires several iterative synthesis steps to identify individual active hit compounds This
use of a scaffold ranking library approach has successfully been used in many assays including:
the identification of metalloprotease ADAM 17 ligands, the identification of novel neurite
outgrowth promoters with nanomolar potency, the discovery of small molecule inhibitors of
human As(III) S-adenosylmethionine methyltransferase (AS3MT) and the identification of new
analgesics through the direct in vivo screening assay [55,56, 57, 58].
1.3.9. Novel Approaches for Screening Compounds: Ring Distortion Strategy to Synthesize
Structurally Diverse Compounds
Natural products may be highly specific to their molecular targets, given their complex
chiral structures, containing a plethora of functional groups necessary to form the highly specific
binding interactions needed. A new approach called Complexity-to-Diversity (CtD) has been
developed to capitalize on this [41]. Using the CtD approach, a natural product undergoes a series
of different chemoselective reactions, causing a dramatic alteration of the natural product’s ring
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systems, which are already innately complex [41]. The goal of this approach is to generate
additional small molecules possessing a biological activity that is distinct from the parent
compound. The end result is a library of structurally unique scaffolds that are diverse and highly
complex. Ultimately, this should allow for the identification of novel scaffolds that display unique
biological activities compared to the starting structure [41].
The Huigen’s laboratory at University of Florida has been focusing its efforts on Ring
Distortion strategies using natural products, such as the indole alkaloids Yohimbine and
Vincamine. This strategy involves dramatic changes to scaffold rings through simple synthetic
routes to create a library of molecules with diverse scaffold structures [41]. A major avenue for
this work is the re-engineering of a molecule to have a new biological target by using a starting
material that is already biologically active, while still having advantages over more simple
compounds. One of the limitations of simple compounds, is that many of the more complex targets
elude them. Ring distortion of yohimbine, an indole alkaloid, led to a library of complex and
unique scaffolds. Yohimbine is an indole alkaloid isolated from the bark of Pausinystalia trees and
acts as an α2-adrenergic receptor antagonist. Yohimbine is highly abundant and is sold over-thecounter for its fat-burning/stimulatory and aphrodisiac properties. Given its high degree of
availability, Yohimbine is a great starting material for Ring-Distortion strategy [41].
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Figure 2. Ring Distortion Strategy .Ring distortion utilizes natural products as a chemical
starting point for the discovery process, transforming them into diverse compounds through ring
cleavage, ring expansion, ring fusion, and ring rearrangement reactions. Source: Paciaroni N,
R.R., Matthews J, Norwood V, Arnold A, Dang L, Luesch H, Huigens R, A Tryptoline Ring
Distortion Strategy Leads to Complex and Diverse Biologically Active Molecules from the Indole
Alkaloid Yohimbine. Chemistry, 2017. 23(18): p. 4327-4335.
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Figure 3. Molecular Properties of Yohimbine Ring Distortion Library. (A)Stereochemical
complexity of Y Series compared to FDA drugs and Chembridge Library. (B) Fsp3 hybridization
of Y Series compounds compared to FDA drugs and ChemBridge Library. Source: Paciaroni N,
R.R., Matthews J, Norwood V, Arnold A, Dang L, Luesch H, Huigens R, A Tryptoline Ring
Distortion Strategy Leads to Complex and Diverse Biologically Active Molecules from the Indole
Alkaloid Yohimbine. Chemistry, 2017. 23(18): p. 4327-4335.
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CHAPTER 2: MATERIALS AND METHODS
2.1. In vitro cultivation of Plasmodium falciparum
Chloroquine resistant P. falciparum Dd2 and drug sensitive P.falciparum 3D7 strains were
cultured using a modified Trager and Jensen technique. [43]. Parasite strains were cultured in
RPMI1640 (Invitrogen) media supplemented with Dextrose, Hypoxanthine, Sodium Bicarbonate,
HEPES, and Albumax II. Cultures were maintained at 5% parasitemia, 4% hematocrit, and
incubated at 37°C in a gas mixture of 5% CO2 and 95% O2. Media was changed daily.

2.2. SYBR Green-I Assay to Discover Antimalarials
Compounds were diluted into dH2O and added to culture media containing asynchronous
P.falciparum Dd2 or 3D7 strains at 1% parasitemia, 2% hematocrit [44,45,46]. Care was taken to
avoid concentrations above 0.2% DMSO which could illicit toxicity in the parasite. Maximum
inhibition controls were performed using Chloroquine at 1µM, and minimum inhibition controls
were left untreated. After culture was added, plates were shaken at 550 RPM for five minutes
before being incubated for 72 hours at 37°C[26]. Following the drug incubation period, each plate
was frozen at -80°C. After being thawed and allowed to equilibrate to room temperature, 100 µL
of lysis buffer containing 20mM Tris-HCL, 0.08% Saponin, 5mM EDTA, 0.8%Triton X-100, and
0.01% SYBR Green I was added to each well before plates were incubated in the dark for 1 hour
at room temperature. Fluorescence was read using a Synergy H4 plate reader (Biotek) with 485
nm excitation and 530 nm emission.
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2.3. Cytotoxicity Assay
Hit compounds were evaluated for cytotoxicity using HEPG2 cells. 384 well plates were
seeded with 2,500 cells/well, with a well volume of 50 µL, and incubated for 24 hours to allow
the cells to adhere. Test inhibitors were serially diluted and added to the plate and Digitonin (or
5% Triton X 100) was added as a control for maximum % inhibition. Plates were incubated at
37°C for 48 hours before 10 µL MTS ([(3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) was added to each well. Following
MTS addition, samples were incubated for 4 hours and cell viability was measured using A490
with a Synergy H4 plate reader (Biotek).
2.4. Physicochemical Profiling
The physicochemical profile of top hits was determined by (….). The chemical descriptors
CLogP, molecular weight, hydrogen bond donor and acceptor, and tPSA were calculated using
Chemdraw. Mouse microsomal stability was measured using mouse liver microsomes with or
without NADPH. Solubility a pH 7.4 was calculated using UV-Vis absorption. Permeability was
measured using an artificial permeability assay.
2.5. Determination of Stage Specific Action
P. falciparum Dd2 parasites were synchronized using a magnetic column to collect late
stage schizonts, followed 8 hours later by treatment with 5% sorbitol to eliminate all but the
recently invaded ring stage parasites. A stage specific action study was performed roughly 48 hours
later using parasites at 6 HPI (47). 200 µL of synchronized culture at 2% parasitemia 2%
hematocrit was added to each well of a 96 well plate. In order to determine the developmental
stage that the compounds act on, inhibitors at 5x EC50 were added at either 6, 18, 30, or 42 HPI.
Parasites were harvested every 12 hours from each treatment group until 54 HPI. Giemsa smears
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were taken at each collection, and the remaining parasites were fixed in 0.25% Glutaraldehyde in
PBS. Following sample collection, samples were permeabilized for 10 minutes with 0.2% Triton,
and treated with 0.05mg/mL RNAse A for 3 hours at 37°C to remove any remaining RNA. Parasite
DNA was then stained overnight with 500 nM of YOYO-I [27]. Samples were read using a
Beckman CYTOFLEXS. Unstained sample and uninfected RBCS were used to gate the uninfected
RBC population. Parasite stage was determined using the FL-1A/FITC-A emission filter.
2.6. Rate of Parasite Killing Assay
To determine how quickly hit compounds act upon the parasite, asynchronous Dd2 cultures
at 5% parasitemia, 2% hematocrit were exposed to 5x EC50 inhibitor concentration for either 6,
12, 24, or 48 hours (48,49). After incubation, culture was washed three times with media before
being resuspended in culture media. Giemsa smears were performed every 24 hours to monitor
parasite growth. Compounds showing greater than 90% inhibition within 12 hours of inhibitor
exposure, such as Dihydroartimisinin, were considered fast acting. Compounds showing greater
than 90% inhibition within 24 hours of inhibitor exposure, such as Chloroquine, were considered
intermediate acting. Inhibitors that required longer incubation times were considered to be slow
acting. Inhibitors that prevented subsequent parasite growth following removal were deemed
parasiticidal. Meanwhile, inhibitors such as atovaquone, were classified as parisitostatic if cultures
returned to normal growth following inhibitor removal.
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CHAPTER 3: IDENTIFICATION OF BIS-CYCLIC GUANIDINES AS
ANTIPLASMODIAL COMPOUNDS FROM POSITIONAL SCANNING
MIXTURE-BASED LIBRARIES [70]
3.1 Positional Scanning Mixture-Based Libraries
Using combinatorial chemistry, positional scanning combinatorial libraries can be rapidly
synthesized and analyzed without robotics. We screened the Torrey Pines Institute for Molecular
Studies (TPIMS) proprietary high-density combinatorial libraries that were targeted toward the
discovery of novel antimalarial lead compounds [42,50]. The TPIMS collection of libraries
contains a large number of small molecule compounds residing largely in the underexplored areas
of chemical space [42, 50, 51, 52, 53 ]. Each of the 81 small molecule libraries is arranged in a
positional scanning format and made up of 100–200 mixture samples [42]. These mixture samples
are systematically formatted so that the activities of individual compounds can be predicted from
the screening of exponentially fewer samples.

Figure 4. Screening of scaffold ranking library for preliminary screen activity. Source:
Perry, DL., Roberts, BF., Debevec, G., Michaels, HA., Chakrabarti, D., Nefzi, A. Identification
of Bis-Cyclic Guanidines as Antiplasmodial Compounds from Positional Scanning Libraries.
Molecules., 2019, 24, 1100; doi:10.3390/molecules24061100 To assess the antiplasmodial
potency of the TPIMS small molecule compounds, we pursued an unbiased cell-based screening
of the TPIMS Scaffold Ranking Library of 30 million compounds using the SYBR green I-based
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DNA quantification assay for inhibiting malaria parasite proliferation [44, 45, 36]. The scaffold
ranking library provides a method to triage the available TPIMS libraries based on activity [42,
53, 54]. This library is composed of 81 samples forming different small molecule positional
scanning libraries. Each sample of the 81 pharmacophores contains an approximate equal molar
amount of each compound in that library. As an example, the sample of the selected bisimidazolidinimine library 1955 is composed of 738,192 compounds in equimolar amounts. These
sublibraries (all mixtures) were directly prepared in parallel to the library synthesis, or can be
prepared by mixing the 120 samples forming the complete positional scanning library [55]. Thirty
million compounds from 81 separate libraries, built upon 81 disparate scaffolds, identified the TPI1955 bis-cyclic guanidine library to be a potent and selective anti-plasmodial inhibitor.
As our main goal was to overcome drug-resistant malaria, we used the chloroquine (CQ)resistant Pf strain of parasites, Dd2. Assays were performed in 96-well microtiter plates, under
standard culture conditions for 72 h, as described in the experimental section [22, 23, 24]. All
plates contained control wells: (a) 0.1% dimethyl formamide (DMF) solvent control and (b) 1 _M
and 100 nM chloroquine. Z-factors were calculated, and only assays with values > 0.7 were
considered for evaluation. We also monitored for the compounds any autofluorescence or cell lysis
properties. The library mixtures contained between 2,016 compound mixtures and 18.9 million
individual compounds. Figure 1 shows the results of the screening of TPIMS scaffold ranking
libraries at 10 µg/mL. Fourteen libraries exhibited a > 80% inhibition of Pf Dd2 growth upon 72
h exposure; of which, four libraries (2275, 1955, 2291, and 2157) showed good selectivity (> 15
fold) when tested for cytotoxicity against the HepG2 human hepatoma cells. Based on the results
of the scaffold ranking library plate and structural features, we selected the pyrrolidine bis-cyclic
guanidine library TPI-1955 for subsequent deconvolution [22, 23, 24].
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Figure 5. Identification of active groups at positions R1-R4 in the compound mixture.
Source: Perry, DL., Roberts, BF., Debevec, G., Michaels, HA., Chakrabarti, D., Nefzi, A.
Identification of Bis-Cyclic Guanidines as Antiplasmodial Compounds from Positional Scanning
Libraries. Molecules., 2019, 24, 1100; doi:10.3390/molecules24061100

Figure 6. Synthesis of pyrrolidine bis-cyclic guanidines from resin-bound acylated
tetrapeptides. Perry, DL., Roberts, BF., Debevec, G., Michaels, HA., Chakrabarti, D., Nefzi, A.
Identification of Bis-Cyclic Guanidines as Antiplasmodial Compounds from Positional Scanning
Libraries. Molecules., 2019, 24, 1100; doi:10.3390/molecules24061100
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We have screened 120 mixture samples of the 1955 positional scanning library (bis-cyclic
guanidine) with a total diversity of 738,192 compounds. The mixture samples from positional
scanning libraries were evaluated at 500 ng/mL per mixture. The selection of the most active
mixtures guided the synthesis of individual compounds. Figure 5 outlines a Positional Scanning
Synthetic Combinatorial Library TPI-1955, having four sites of diversity, and consisting of four
separate sub-libraries, each having a single defined position (R), and mixture positions (X) [39,59].
Figure 7 illustrates the use of such a library to identify the most active groups at each position of
the selected pyrrolidine bis-cyclic guanidine library (TPI-1955) directly from the initial screening
data.

Figure 7. Deconvolution of positional scanning pyrrolidine bis-cyclic guanidine library
TPI-1955 and synthesis of individual compounds TPI-2459. Source: Perry, DL., Roberts, BF.,
Debevec, G., Michaels, HA., Chakrabarti, D., Nefzi, A. Identification of Bis-Cyclic Guanidines
as Antiplasmodial Compounds from Positional Scanning Libraries. Molecules., 2019, 24, 1100;
doi:10.3390/molecules24061100
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The screening of the four sets of mixtures (Figure 7), totaling 120 samples for testing,
provided information about the most important groups of each variable position in the TPI-1955
library containing 738,192 unique compounds. Three mixtures with a defined position R1,
corresponding to the amino acids (L-phenylalanine, L-isoleucine and L-serine), two mixtures with
a defined position R2, corresponding to the amino acids (L-serine and L-valine), three mixtures
with a defined position R3, corresponding to the amino acids (glycine, L-norvaline, and Dnorvaline), and four mixtures with a defined position R4, corresponding to the carboxylic acids
(meta trifluoromethyl tolyl acetic acid, 3-methoxyphenylacetic acid, butyric acid, and 4methylvaleric acid), yielded good inhibition activity. The parallel synthesis of all individual
compounds named TPI-2359 derived from the deconvolution of TPI-1955 representing the
combination of all active mixtures with defined R1, R2, R3, and R4 (Figure 6) was performed
using the strategy outlined in Figure 7.
The data show significant differentiation in activity levels among the samples tested at each
position, a key feature for deconvoluting a positional scanning library. Moreover, some
preliminary SAR can be determined from the library screening. High activity is observed with
compounds having small aliphatic groups at positions R1, R2, and R3, and aromatic and aliphatic
groups in position R4. The (S) sec-butyl group is preferred in position R1, while the (S) isopropyl
group and (S) hydroxymethyl are preferred in position R2. In position R3, the n-propyl is preferred
with no preference for configuration.
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Figure 8. Structures and activity of identified top antiplasmodial hits. Source: Perry, DL.,
Roberts, BF., Debevec, G., Michaels, HA., Chakrabarti, D., Nefzi, A. Identification of Bis-Cyclic
Guanidines as Antiplasmodial Compounds from Positional Scanning Libraries. Molecules.,
2019, 24, 1100; doi:10.3390/molecules24061100
All compounds were purified and screened against the Pf Dd2 strain, compounds with EC50
activity ranging between 201 and 350 nM were identified (Figure 9). As a counter screen, we
evaluated the cytotoxicity of these compounds in human hepatocyte cell line HepG2 using MTS
cell proliferation assay [61]. The compounds exhibited very promising selectivity of >60.
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3.2. TPI 2359-47 Inhibits Intraerythrocytic Plasmodium at Schizont Stage
To gain insight into the mechanism of action of this scaffold in Plasmodium, we determined
the stage‐specificities of one of the most potent analogs—TPI 2359‐47—by exploring its effects
on the intraerythrocytic development of the parasite. A tightly synchronized Pf Dd2 culture was
exposed to a 5x EC50 concentration of the compound at 6 (ring stage), 18 (trophozoite stage), 30
(schizont stage), and 42 HPI. The effect of TPI 2359‐47 on developmental stage progression was
assessed via flow cytometry of fixed YOYO‐1 stained Pf parasites collected at designated time
intervals. As seen in Figure 10A, the control culture matured to rings at 54 HPI. In contrast, the
maturation of the TPI 2359‐47 treated culture was blocked in an early stage. This was clearly
evident from the flow cytometric data presented in the right panel. Figure 10B shows that the TPI
2359-47 treated cells did not mature beyond the trophozoite stages. Treatment of the culture at 18
HPI had similar effects (data not shown). Interestingly, exposing the culture to TPI 2359‐47 at 30
HPI blocks at the schizont stage (Figure 11 A,B), while the treatment at the segmenter stage at 42
HPI had no effect on maturation (Figure 11 C,D). This suggests that TPI 2359‐47 acts on a cellular
target whose activity is important for parasite maturation during ring through schizont stages but
not at the segmenter stage. In addition, we checked the plasma stability of compound TPI 2359‐
47. Compound was incubated in rat plasma for up to 5 h and showed no significant degradation
using HPLC/MS.
Different bis‐cyclic guanidine libraries, including TPI‐1955, were also screened against
other targets and organisms, including inhibiton of tyrosine recombinases, inhibition of Holliday
junction‐resolving enzymes [30], leishmaniasis [62], and bacteria [63,64]. Their deconvolution led
to the identification of active compounds in each assay. The activities of these individual
compounds we have found were highly specific to each molecule identified. Typically, none of
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the synthesized individual compounds for a specific target had significant activity at other targets.
Thus, the activity likely due to a combination of the scaffold itself and the differing substituent R
groups. For example, a simple change of the stereochemistry (L and D amino acids) usually leads
to loss of activity. Many positively charged and/or aromatic peptides have been reported as having
widespread activity against infectious diseases not limited to malaria.. The positively charged
amino acid residues, such as arginine and lysine, were shown to play an important role in the
activity of antimicrobial peptides, as a result of the electrostatic interactions between the identified
peptides and bacterial membranes [65,66,67]. Of importance, not all peptides which contain these
amino acids had significant activity. It is the combination of the location of the functional groups
with the location on the central scaffold and the peptide conformation that drives the specific
activity. The same is true for the various nonpeptide bis-cyclic guanidines we have synthesized
and tested. It is not surprising to find active compounds from such libraries, but the majority of the
compounds have little to no activity.
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Figure 9. Stage-specific inhibition of Plasmodium growth by TPI 2359-47. Tightly
synchronized parasites were treated at 6 HPI with 5x EC50 concentration of the chemotype. (A)
Microscopic-evaluation of Giemsa-stained thin smears in the left. Histogram plot of YOYO-1
labeled cells following treatment of the compound were shown in the right. (B) Distribution of
developmental stages at different time intervals following treatment of the compound at 6 HPI.
Three replicates of 1,000 parasitized erythrocytes were counted to determine stage-specific
distribution. DHA, dihydroartemisinin. Source: Perry, DL., Roberts, BF., Debevec, G., Michaels,
HA., Chakrabarti, D., Nefzi, A. Identification of Bis-Cyclic Guanidines as Antiplasmodial
Compounds from Positional Scanning Libraries. Molecules., 2019, 24, 1100;
doi:10.3390/molecules24061100
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Figure 10. Stage-specific inhibition of Plasmodium growth by TPI 2359-47. (A) Microscopic
evaluation of Giemsa-stained thin smears and flow cytometric analysis of the YOYO-1 labeled
cells to measure DNA content after exposure to inhibitor (5x EC50) at 30 HPI. (B) Distribution of
different stages when the culture was treated at 30 HPI. (C,D) Effect following exposure of the
parasite to the compound at 42 HPI. Three replicates of 1,000 parasitized erythrocytes were
counted to determine stage-specific distribution. DHA, dihydroartemisinin. Source: Perry, DL.,
Roberts, BF., Debevec, G., Michaels, HA., Chakrabarti, D., Nefzi, A. Identification of Bis-Cyclic
Guanidines as Antiplasmodial Compounds from Positional Scanning Libraries. Molecules.,
2019, 24, 1100; doi:10.3390/molecules24061100
In conclusion, the screening of a large complex library using a demonstrated synthetic
screening approach led to the rapid identification of antiplasmodial compounds with novel
activity against the chloroquine resistant Dd2 strain. This suggests that Bis-cyclic guanidine
compounds could be promising for the future development of antimalarials. In particular, the
effect of TPI 2359-47 on schizonts is noteworthy, as only artemisinins among current
antimalarials demonstrates schizonticidal activities [68]. Our study underscores the utility of the
positional scanning libraries in the rapid identification of novel antiplasmodial hits similar to
previous large-scale screening of expansive pharmaceutical libraries [34]. Future studies of these
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antiplasmodial compounds identified will focus on SAR to further improve the potency prior to
in vivo testing.
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CHAPTER 4: RE-ENGINEERING OF YOHIMBINE’S BIOLOGICAL
ACTIVITY THROUGH RING DISTORTION: IDENTIFICATION AND
STRUCTURE-ACTIVITY RELATIONSHIPS OF A NEW CLASS OF
ANTIPLASMODIAL AGENTS [71]
4.1 Ring Distortion Screening
To commence antiplasmodial screening utilizing the ring distortion approach, a library of
70 yohimbine-derived ring distortion scaffolds was tested for activity against the Dd2 strain in a
single concentration SYBR Green I assay at 2 µM. Several compounds showed a greater than 40%
inhibition of parasite growth at 2 µM. These hit compounds and their related analogs were further
subjected to dose response experiments to determine the EC50 values and to gather additional
information as to their structure activity relationships (SAR).

Figure 11. Complex and diverse scaffolds rapidly synthesized from the indole alkaloid
yohimbine. Initial hit compounds possessing antiplasmodial activities are highlighted; however,
yohimbine was found to demonstrate no antiplasmodial activity. The remainder of the
yohimbine-derived scaffolds (Y2-Y6) were found to be inactive against P. falciparum Dd2 cells
during initial screens. Source: Paciaroni, NG., Perry, DL., Norwood, VM., Murillo-Solanno, C.,
Collins, J., Tenneti, S., Chakrabarti, D. Huigens, RW. Re-Engineering of Yohimbine’s
Biological Activity through Ring Distortion: Identification and Structure-Activity Relationships
of a New Class of Antiplasmodial Agents. ACS Infectious Diseases., 2020, 6(2), 159-167.
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4.2 Yohimbine Structure Activity Relationship
An initial library of 70 yohimbine-derived ring-distorted compounds was screened for
antiplasmodial activity against a chloroquine-resistant P. falciparum strain (Dd2) in an unbiased,
cell-based SYBR Green I assay (Figure 10) [44,45,46]. From the initial screen, compounds from
the Y1 and Y7 series demonstrated inhibitory activity against Dd2 cells (> 40% at 2 μM). Active
hits and structurally related analogs were subsequently subjected to dose−response experiments to
generate comparative EC50 values to determine overall potency and gain initial insights into the
SAR. Interestingly, all hit compounds arose from two of the ring-distorted scaffolds accessed from
yohimbine; including the Y1 series (6 analogues, synthesized in three steps from yohimbine, EC50
= 1.60−5.18 μM against Dd2), and the Y7 series (8 analogues, synthesized in four steps from
yohimbine, EC50 values ranging from 0.33 to 2.57 μM against Dd2) (Figure 11).
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Figure 12. Antiplasmodial activities of Y1 and Y7 series analogues. Testing of related
analogues which were found to be active during initial screens against Dd2 cells provided initial
SAR insights and informs follow-up chemical synthesis. Source: Paciaroni, NG., Perry, DL.,
Norwood, VM., Murillo-Solanno, C., Collins, J., Tenneti, S., Chakrabarti, D. Huigens, RW. ReEngineering of Yohimbine’s Biological Activity through Ring Distortion: Identification and
Structure-Activity Relationships of a New Class of Antiplasmodial Agents. ACS Infectious
Diseases., 2020, 6(2), 159-167.
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From the initial screen, dibenzylated spiro-oxindole analogue Y7j, proved to be the most
potent compound of the library (EC50= 0.33 μM) (Figure 11), and showed no cytotoxicity against
HepG2 cells at 40 μM (highest concentration tested). This demonstrated a clear selectivity for
plasmodial parasites over human cels (selectivity index > 121, as determined by HepG2 EC50/Dd2,
EC50). In addition, the parent indole alkaloid yohimbine was completely inactive against Dd2 cells
(EC50 of 76.7 μM), demonstrating a re-engineering of its biological activities had occurred through
the dramatic altering of its molecular architecture.

Figure 13. Characterization of stage-specific activity of Y7j in Dd2 cells. Tightly
synchronized Dd2 cultures were treated at 6 h time points with Y7j at 5x EC50. Blood smears and
Giemsa staining were also taken at each time point to verify (A) phenotype and (B) flow
cytometry. (C) Parasitemia of Y7j treated and vehicle untreated cultures. Notes:
dihydroartemisinin (DHA), an inhibitor of the late ring/ early trophozoite stage, was tested as a
positive control alongside Y7j (not shown). HPI, hours post-invasion of red blood cells by
merozoites. Source: Paciaroni, NG., Perry, DL., Norwood, VM., Murillo-Solanno, C., Collins, J.,
Tenneti, S., Chakrabarti, D. Huigens, RW. Re-Engineering of Yohimbine’s Biological Activity
through Ring Distortion: Identification and Structure-Activity Relationships of a New Class of
Antiplasmodial Agents. ACS Infectious Diseases., 2020, 6(2), 159-167.
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4.3 Y7j Inhibits Intraerythrocytic Plasmodium at the Trophozoite Stage
To further investigate the antiplasmodial activity of Y7j, we evaluated the developmental
stage-specific action of this small molecule via microscopy and flow cytometry. Precise
delineation of the timing of action of an inhibitor provides valuable insight into the molecular
underpinnings of the inhibitor and its effect on the developmental growth of the parasite [37,38].
Tightly synchronized parasites were treated at 6 HPI with ~5x EC50 concentration of Y7j (Figure
12A). Microscopic evaluation of Giemsa-stained-thin smears and flow cytometric assessments
were performed at 12 h intervals. Negative controls represented infected red blood cells exposed
to vehicle DMSO (0.1%) only. Y7h treated cultures (Figure 13 A,B) shows the compound inhibited
the parasite’s late ring/trophozoite stage (18 HPI) [43][ (Figure 13 A,B), compared to untreated
cultures [43]. The untreated control culture matures the phenotype expected through the
trophozoite/schizont (30 HPI) and segmenter (42 HPI), and reappears as rings after reinvasion (54
HPI) with a concomitant increase in parasitemia (see flow cytometry data, Figure 12B,C).
Although at the trophozoite stage (30 HPI) the mass increased in Y7j treated parasites, there was
significant vacuolization noticed. Interestingly, Y1f also demonstrated stage-specific action at the
late ring/trophozoite phase in Dd2 cells, and vacuolization similar to Y7j. These two ring distortion
scaffolds, Y1 and Y7, are very different from each other structurally and likely operate through
different primary modes of action against plasmodial parasites.
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Figure 14. Rate of killing and parasiticidal/parasitostatic determination of Y7j in Dd2
cultures. To evaluate the rate of killing for Y7j, asynchronous cultures were treated with 5 x
EX50 (Y7j concentrations) for (A) 6, (B) 12, (C) 24, or (D) 48 h. After each treatment, cultures
were washed three times in RPMI, then resuspended in culture media, and monitored daily for
parasite growth. Note: DMSO concentration was 0.15% for these experiments.
Dihydroartemisinin (DHA) was used as a positive control for rapid parasite killing (test
concentration = 50 nM; 5x EC50) in these experiments. Source: Paciaroni, NG., Perry, DL.,
Norwood, VM., Murillo-Solanno, C., Collins, J., Tenneti, S., Chakrabarti, D. Huigens, RW. ReEngineering of Yohimbine’s Biological Activity through Ring Distortion: Identification and
Structure-Activity Relationships of a New Class of Antiplasmodial Agents. ACS Infectious
Diseases., 2020, 6(2), 159-167.

4.4 Y7j is Parasiticidal
Fast acting (inhibitor exposure of 24 hours or less) parasiticidal compounds are desirable
for the treatment of malaria infections in a clinical setting. Slow acting and parisitostatic inhibitors
fail to clear Plasmodium infections, and are prone to recrudescence of the parasite. To determine
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if Y7j elicits antiplasmodial activity through a parasiticidal or parisitostatic mechanism, we
performed a series of kill kinetic experiments in Dd2 cultures [41,42]. We treated asynchronous
parasite cultures with a 5 x EC50 concentration of the compound for different periods of time (6,
12, 24, or 48 h). After washing off the compound at these time points, growth of the culture was
evaluated for 96 h. As is evident from these kill kinetic experiments (Figure 13), the significant
reduction in parasitemia observed following a 24 h treatment with Y7j, suggests this compound is
a fast-acting parasiticidal agent with rapid clearance of the remaining parasites 48 h post-treatment.
Similar to Y7j, significant killing of Dd2 cells was observed following a 24 h treatment of Y1f.
After generating additional Y7j and Y1f analogues, all compounds were subjected to
dose−response experiments to determine the EC50 values against Dd2 parasites. The two new Y1f
analogues were found to be inactive (Y1i and Y1j EC50 > 20 μM), and analogues related to the Y1
series were no longer pursued during these investigations. On the other hand, six new Y7j
analogues demonstrated sub micromolar antiplasmodial activities, with thiophene analogue Y7p
(EC50 = 0.32 μM), and 2-chlorobenzyl analogue Y7n (EC50 = 0.52 μM), being the most potent new
analogues synthesized.
From these studies, an interesting SAR profile was revealed for the new antiplasmodial
agent Y7j and its related analogues. The most prominent structural feature regarding
antiplasmodial activity of Y7j is the requirement of both 2-chloro-4-methoxybenzyl groups, as
removal of either group led to a complete loss in antiplasmodial activity (e.g., Y7ab, EC50 > 20
μM). This SAR information could not have been obtained without the new synthetic efforts, which
allowed for a complementary series of monobenzylated analogues for biological investigations. In
total, seven monoalkylated/ benzylated analogues of Y7j (containing either a free amide or a free
hydroxyl group) were investigated during these studies, and each of these analogues reported an

38

EC50 > 20 μM (e.g., Y7aa and Y7ae). In addition, subtle structural changes were made to Y7j
through alkylation of Y7b with alternative benzyl and heterobenzyl starting materials. Removal of
the methoxy groups at the 4-position of both benzyl moieties of Y7j resulted in a 1.6-fold loss in
antiplasmodial activity against Dd2 parasites (Y7n, EC50 = 0.52 μM). At the same time, removal
of the 2-chlorine atom of Y7j resulted in a 4.5-fold loss in antiplasmodial activity (Y7m, EC50 =
1.51 μM). Additional substitutions with six-membered heterocycles containing nitrogen also
resulted in losses in activity compared to Y7j (see Figure 12 for detailed SAR profiling).
Interestingly, the only new compound to demonstrate equipotent activity against Dd2 cells
compared to Y7j was thiophene analogue Y7p (EC50 = 0.32 μM). Y7p also demonstrated stagespecific activity at the late ring/trophozoite phase of asexual blood stage against Dd2 cells, similar
to Y7j (Table 1), as previously mentioned.
In addition to SAR, seven Y7 analogues were counter-screened in dose−response
experiments against wild-type 3D7 P. falciparum parasites, and each analogue demonstrated near
equipotent activity when comparing EC50 values to those generated against chloroquine-resistant
Dd2 parasites (Table 1). Additionally, the same seven Y7 analogues demonstrated no cytotoxicity
against HepG2 cells (EC50 > 40 μM, selectivity indexes from > 45 to > 125, Table 1). These
combined analyses point to a clear SAR, allowing us to hypothesize that the structural
requirements for active analogues related to Y7j result from such analogues interacting with a
well-defined biological target. On the basis of our SAR profile, we predict these agents to elicit
their activities against a unique antiplasmodial target. Additional mechanistic studies are required
to substantiate this hypothesis and are currently being pursued.
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Table 1. Summary of Antiplasmodial Activities and Cytotoxicity against HepG2 (liver)
Cells for Y and Select Y1 and Y7 Analogues.
EC50 Dd2
EC50 3D7
EC50 HepG2
Selectivity
Stage-Specificcells (µM)
cells (µM)
cells (µM)
Index (SI)
Activity
Y
>100
N/A
76.7 ± 0.74
Y1c
2.58 ± 0.07
Y1e
2.98 ± 0.20
Y1f
18.9
A
1.60 ± 0.16
Y1g
3.18 ± 0.11
Y1h
3.47 ± 0.11
Y7e
1.50 ± 0.06
Y7f
1.41 ± 0.23
Y7g
>40
>51
A
0.79 ± 0.06
0.74 ± 0.07
Y7h
1.05 ± 0.08
Y7i
0.85 ± 0.05
Y7j
>40
>121
A
0.33 ± 0.03
0.35 ± 0.03
Y7k
0.64 ± 0.07
0.68 ± 0.07
Y7l
2.57 ± 0.05
Y7m
1.51 ± 0.06
Y7n
>40
>77
0.52 ± 0.04
0.56 ± 0.04
Y7o
3.51 ± 0.32
Y7p
>40
>125
A
0.32 ± 0.02
0.49 ± 0.05
Y7q
>40
>46
0.87 ± 0.04
0.91 ± 0.03
Y7r
>40
>62
0.65 ± 0.07
0.68 ± 0.09
Y7s
1.32 ± 0.07
1.13 ± 0.09
Y7t
3.08 ± 0.20
4.31 ± 0.16
Y7u
>40
>45
0.89 ± 0.05
0.80 ± 0.09
Y7aj
2.38 ± 0.24
Y7ak
0.94 ± 0.10
Y7am
2.71 ± 0.07
3.00 ± 0.13
*All concentrations are reported in micromolar (µM). Notes “A” or stage-specific activity at the
late ring/trophozoite phase of the asexual blood stage of P. falciparum. Selectivity index (SI) was
generated according to the EC50 against HepG2 cells divided by the EC50 against Dd2 cells. All
values reported in this table resulted from three independent experiments. Source: Paciaroni,
NG., Perry, DL., Norwood, VM., Murillo-Solanno, C., Collins, J., Tenneti, S., Chakrabarti, D.
Huigens, RW. Re-Engineering of Yohimbine’s Biological Activity through Ring Distortion:
Identification and Structure-Activity Relationships of a New Class of Antiplasmodial Agents.
ACS Infectious Diseases., 2020, 6(2), 159-167.
Y Code
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Figure 15. Detailed structure-activity relationship profiles regarding the antiplasmodial
activities of Y7j. Source: Paciaroni, NG., Perry, DL., Norwood, VM., Murillo-Solanno, C.,
Collins, J., Tenneti, S., Chakrabarti, D. Huigens, RW. Re-Engineering of Yohimbine’s
Biological Activity through Ring Distortion: Identification and Structure-Activity Relationships
of a New Class of Antiplasmodial Agents. ACS Infectious Diseases., 2020, 6(2), 159-167.
In conclusion, we have identified two diverse and complex scaffolds that possess
antiplasmodial activities from the ring distortion efforts of the indole alkaloid yohimbine. The antiplasmodial compound Y1f demonstrated a moderate potency when screened against chloroquine
resistant P. falciparum Dd2 parasites (EC50 = 1.60 µM). Meanwhile, the antiplasmodial compound,
Y7j, was found to demonstrate good potency against chloroquine-resistant P. falciparum Dd2
parasites (EC50 = 0.33 μM) without eliciting cytotoxicity against human HepG2 cells (EC50 > 40
μM, selectivity index > 121). In addition, Y7j demonstrated stage-specific action against P.
falciparum at the late ring/trophozoite stage, preventing an increase in parasitemia as determined
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by flow cytometry. It also showed rapid parasiticidal activity against Dd2 cultures following a 24
h incubation.
A series of focused analogues were also synthesized to gain detailed SAR insights, and we
learned that both the benzyl groups of Y7j are required for activity. The fine-tuning of
antiplasmodial activities then, could be accomplished by changing the substitution patterns on the
benzyl moieties. However, the only new analogue to demonstrate equipotent activity to Y7j was
the thiophene bioisostere, Y7p. Interestingly, the parent indole alkaloid yohimbine demonstrated
no antiplasmodial activities, and our active scaffolds are the result of the re-engineering of
yohimbine’s biological activity. This work demonstrates the potential for the ring distortion of
indole alkaloids to drive new discoveries in both chemical biology and drug discovery.
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CHAPTER 5: SUMMARY
Through this work, positional scanning and ring distortion libraries have been established
that are capable of identifying promising antiplasmodial compounds. Both hits identified
underwent additional screening to uncover their unique mechanisms of action . The effect of TPI
2359-47 on schizonts is noteworthy as only artemisinins among current antimalarials demonstrate
schizonticidal activities. Meanwhile, Y7j demonstrated stage-specific action against P. falciparum
at the late ring/trophozoite stage.
The screening of a large complex library using a demonstrated synthetic and screening
approach led to the rapid identification of antiplasmodial compounds which exhibited interesting
antimalarial activity against the chloroquine resistant Dd2 and drug sensitive 3D7 strains. These
results suggest that Bis-cyclic guanidine compounds have the promise to be effective in malaria
therapy. As mentioned previously, the effect of TPI 2359-47 on schizonts is noteworthy as only
artemisinins among current antimalarials demonstrate schizonticidal activities [68]. Our study
underscores the utility of the positional scanning libraries in rapid identification of novel
antiplasmodial hits similar to previous large-scale screening [33] of large pharmaceutical libraries.
Future studies of the antiplasmodial compounds identified from this library will focus on SAR to
further improve the potency against plasmodium, reduce cytotoxicity, and improve stability.
From the ring distortion efforts of the indole alkaloid yohimbine, we have identified two
diverse and complex scaffolds that possess antiplasmodial activity. One new antiplasmodial
compound, Y7j, was found to demonstrate good potency against chloroquine-resistant P.
falciparum Dd2 strain (EC50 = 0.33 μM) without eliciting cytotoxicity against HepG2 cells (EC50
> 40 μM, selectivity index > 121). In addition, Y7j demonstrated stage-specific action against P.
falciparum at the late ring/trophozoite stage, preventing an increase in parasitemia as determined
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by flow cytometry. It also demonstrated rapid parasiticidal activity against Dd2 cultures with only
24 h of incubation. A series of focused analogues were also synthesized to gain detailed
structure−activity relationship insights. Screening of these yohimbine derived CtD analogs
indicated that both benzyl groups of Y7j are required for activity and that fine-tuning of
antiplasmodial activities could be accomplished by changing substitution patterns on the benzyl
moieties. This work demonstrates the potential for the ring distortion of indole alkaloids to drive
new discoveries in chemical biology and drug discovery. Future works regarding Y7j include
pursuing target identification via the in vitro evolution of resistance. Once the molecular target of
Y7j has been identified, efficacy of the scaffold can be improved through structure guided
synthesis.
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